COVID-19 Medicine - Global 麻豆原创 Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB510243320

Publication Date:

October 24, 2024

Pages:

124

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

IT Services [2]

Hardware (Computing & Electronics) [3]

Computing & Electronics [4]

Description:

The global market for COVID-19 Medicine was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.
North American market for COVID-19 Medicine was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for COVID-19 Medicine was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Europe market for COVID-19 Medicine was valued at $ million in 2023 and will reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global key companies of COVID-19 Medicine include Advanz Pharma, Kyung Poong, Mylan, Novartis, Sanofi, Apotex, Bayer, Guangzhou Baiyunshan Guanghua Pharmaceutical and Ipca Laboratories, etc. In 2023, the global five largest players hold a share approximately % in terms of revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for COVID-19 Medicine, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of COVID-19 Medicine by region & country, by Type, and by Application.
The COVID-19 Medicine market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding COVID-19 Medicine.
麻豆原创 Segmentation
By Company
Advanz Pharma
Kyung Poong
Mylan
Novartis
Sanofi
Apotex
Bayer
Guangzhou Baiyunshan Guanghua Pharmaceutical
Ipca Laboratories
Sichuan Sunny Hope
Zydus Cadila
Teva
Sun Pharma
Rising Pharmaceutical
KPC Group
Bristol Laboratories
Shanghai Zhongxisanwei
Shanghai Pharma
Segment by Type:
Tablet
Injection
Segment by Application
Patients With Mild Symptoms
Critically Ill
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of COVID-19 Medicine manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of COVID-19 Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of COVID-19 Medicine in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 麻豆原创 Overview
1.1 COVID-19 Medicine Product Introduction
1.2 Global COVID-19 Medicine 麻豆原创 Size Forecast
1.3 COVID-19 Medicine 麻豆原创 Trends & Drivers
1.3.1 COVID-19 Medicine Industry Trends
1.3.2 COVID-19 Medicine 麻豆原创 Drivers & Opportunity
1.3.3 COVID-19 Medicine 麻豆原创 Challenges
1.3.4 COVID-19 Medicine 麻豆原创 Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global COVID-19 Medicine Players Revenue Ranking (2023)
2.2 Global COVID-19 Medicine Revenue by Company (2019-2024)
2.3 Key Companies COVID-19 Medicine Manufacturing Base Distribution and Headquarters
2.4 Key Companies COVID-19 Medicine Product Offered
2.5 Key Companies Time to Begin Mass Production of COVID-19 Medicine
2.6 COVID-19 Medicine 麻豆原创 Competitive Analysis
2.6.1 COVID-19 Medicine 麻豆原创 Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by COVID-19 Medicine Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in COVID-19 Medicine as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Tablet
3.1.2 Injection
3.2 Global COVID-19 Medicine Sales Value by Type
3.2.1 Global COVID-19 Medicine Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global COVID-19 Medicine Sales Value, by Type (2019-2030)
3.2.3 Global COVID-19 Medicine Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Patients With Mild Symptoms
4.1.2 Critically Ill
4.1.3 Other
4.2 Global COVID-19 Medicine Sales Value by Application
4.2.1 Global COVID-19 Medicine Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global COVID-19 Medicine Sales Value, by Application (2019-2030)
4.2.3 Global COVID-19 Medicine Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global COVID-19 Medicine Sales Value by Region
5.1.1 Global COVID-19 Medicine Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global COVID-19 Medicine Sales Value by Region (2019-2024)
5.1.3 Global COVID-19 Medicine Sales Value by Region (2025-2030)
5.1.4 Global COVID-19 Medicine Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America COVID-19 Medicine Sales Value, 2019-2030
5.2.2 North America COVID-19 Medicine Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe COVID-19 Medicine Sales Value, 2019-2030
5.3.2 Europe COVID-19 Medicine Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific COVID-19 Medicine Sales Value, 2019-2030
5.4.2 Asia Pacific COVID-19 Medicine Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America COVID-19 Medicine Sales Value, 2019-2030
5.5.2 South America COVID-19 Medicine Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa COVID-19 Medicine Sales Value, 2019-2030
5.6.2 Middle East & Africa COVID-19 Medicine Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions COVID-19 Medicine Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions COVID-19 Medicine Sales Value
6.3 United States
6.3.1 United States COVID-19 Medicine Sales Value, 2019-2030
6.3.2 United States COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030
6.3.3 United States COVID-19 Medicine Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe COVID-19 Medicine Sales Value, 2019-2030
6.4.2 Europe COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe COVID-19 Medicine Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China COVID-19 Medicine Sales Value, 2019-2030
6.5.2 China COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030
6.5.3 China COVID-19 Medicine Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan COVID-19 Medicine Sales Value, 2019-2030
6.6.2 Japan COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan COVID-19 Medicine Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea COVID-19 Medicine Sales Value, 2019-2030
6.7.2 South Korea COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea COVID-19 Medicine Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia COVID-19 Medicine Sales Value, 2019-2030
6.8.2 Southeast Asia COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia COVID-19 Medicine Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India COVID-19 Medicine Sales Value, 2019-2030
6.9.2 India COVID-19 Medicine Sales Value by Type (%), 2023 VS 2030
6.9.3 India COVID-19 Medicine Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Advanz Pharma
7.1.1 Advanz Pharma Profile
7.1.2 Advanz Pharma Main Business
7.1.3 Advanz Pharma COVID-19 Medicine Products, Services and Solutions
7.1.4 Advanz Pharma COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.1.5 Advanz Pharma Recent Developments
7.2 Kyung Poong
7.2.1 Kyung Poong Profile
7.2.2 Kyung Poong Main Business
7.2.3 Kyung Poong COVID-19 Medicine Products, Services and Solutions
7.2.4 Kyung Poong COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.2.5 Kyung Poong Recent Developments
7.3 Mylan
7.3.1 Mylan Profile
7.3.2 Mylan Main Business
7.3.3 Mylan COVID-19 Medicine Products, Services and Solutions
7.3.4 Mylan COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.3.5 Novartis Recent Developments
7.4 Novartis
7.4.1 Novartis Profile
7.4.2 Novartis Main Business
7.4.3 Novartis COVID-19 Medicine Products, Services and Solutions
7.4.4 Novartis COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.4.5 Novartis Recent Developments
7.5 Sanofi
7.5.1 Sanofi Profile
7.5.2 Sanofi Main Business
7.5.3 Sanofi COVID-19 Medicine Products, Services and Solutions
7.5.4 Sanofi COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.5.5 Sanofi Recent Developments
7.6 Apotex
7.6.1 Apotex Profile
7.6.2 Apotex Main Business
7.6.3 Apotex COVID-19 Medicine Products, Services and Solutions
7.6.4 Apotex COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.6.5 Apotex Recent Developments
7.7 Bayer
7.7.1 Bayer Profile
7.7.2 Bayer Main Business
7.7.3 Bayer COVID-19 Medicine Products, Services and Solutions
7.7.4 Bayer COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.7.5 Bayer Recent Developments
7.8 Guangzhou Baiyunshan Guanghua Pharmaceutical
7.8.1 Guangzhou Baiyunshan Guanghua Pharmaceutical Profile
7.8.2 Guangzhou Baiyunshan Guanghua Pharmaceutical Main Business
7.8.3 Guangzhou Baiyunshan Guanghua Pharmaceutical COVID-19 Medicine Products, Services and Solutions
7.8.4 Guangzhou Baiyunshan Guanghua Pharmaceutical COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.8.5 Guangzhou Baiyunshan Guanghua Pharmaceutical Recent Developments
7.9 Ipca Laboratories
7.9.1 Ipca Laboratories Profile
7.9.2 Ipca Laboratories Main Business
7.9.3 Ipca Laboratories COVID-19 Medicine Products, Services and Solutions
7.9.4 Ipca Laboratories COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.9.5 Ipca Laboratories Recent Developments
7.10 Sichuan Sunny Hope
7.10.1 Sichuan Sunny Hope Profile
7.10.2 Sichuan Sunny Hope Main Business
7.10.3 Sichuan Sunny Hope COVID-19 Medicine Products, Services and Solutions
7.10.4 Sichuan Sunny Hope COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.10.5 Sichuan Sunny Hope Recent Developments
7.11 Zydus Cadila
7.11.1 Zydus Cadila Profile
7.11.2 Zydus Cadila Main Business
7.11.3 Zydus Cadila COVID-19 Medicine Products, Services and Solutions
7.11.4 Zydus Cadila COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.11.5 Zydus Cadila Recent Developments
7.12 Teva
7.12.1 Teva Profile
7.12.2 Teva Main Business
7.12.3 Teva COVID-19 Medicine Products, Services and Solutions
7.12.4 Teva COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.12.5 Teva Recent Developments
7.13 Sun Pharma
7.13.1 Sun Pharma Profile
7.13.2 Sun Pharma Main Business
7.13.3 Sun Pharma COVID-19 Medicine Products, Services and Solutions
7.13.4 Sun Pharma COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.13.5 Sun Pharma Recent Developments
7.14 Rising Pharmaceutical
7.14.1 Rising Pharmaceutical Profile
7.14.2 Rising Pharmaceutical Main Business
7.14.3 Rising Pharmaceutical COVID-19 Medicine Products, Services and Solutions
7.14.4 Rising Pharmaceutical COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.14.5 Rising Pharmaceutical Recent Developments
7.15 KPC Group
7.15.1 KPC Group Profile
7.15.2 KPC Group Main Business
7.15.3 KPC Group COVID-19 Medicine Products, Services and Solutions
7.15.4 KPC Group COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.15.5 KPC Group Recent Developments
7.16 Bristol Laboratories
7.16.1 Bristol Laboratories Profile
7.16.2 Bristol Laboratories Main Business
7.16.3 Bristol Laboratories COVID-19 Medicine Products, Services and Solutions
7.16.4 Bristol Laboratories COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.16.5 Bristol Laboratories Recent Developments
7.17 Shanghai Zhongxisanwei
7.17.1 Shanghai Zhongxisanwei Profile
7.17.2 Shanghai Zhongxisanwei Main Business
7.17.3 Shanghai Zhongxisanwei COVID-19 Medicine Products, Services and Solutions
7.17.4 Shanghai Zhongxisanwei COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.17.5 Shanghai Zhongxisanwei Recent Developments
7.18 Shanghai Pharma
7.18.1 Shanghai Pharma Profile
7.18.2 Shanghai Pharma Main Business
7.18.3 Shanghai Pharma COVID-19 Medicine Products, Services and Solutions
7.18.4 Shanghai Pharma COVID-19 Medicine Revenue (US$ Million) & (2019-2024)
7.18.5 Shanghai Pharma Recent Developments
8 Industry Chain Analysis
8.1 COVID-19 Medicine Industrial Chain
8.2 COVID-19 Medicine Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 COVID-19 Medicine Sales Model
8.5.2 Sales Channel
8.5.3 COVID-19 Medicine Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Advanz Pharma
Kyung Poong
Mylan
Novartis
Sanofi
Apotex
Bayer
Guangzhou Baiyunshan Guanghua Pharmaceutical
Ipca Laboratories
Sichuan Sunny Hope
Zydus Cadila
Teva
Sun Pharma
Rising Pharmaceutical
KPC Group
Bristol Laboratories
Shanghai Zhongxisanwei
Shanghai Pharma

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.